Ann: Quarterly Activities Report and Appendix 5B - 30 Sept 21, page-97

First 97 Last

Share
Profile

Follow
Scoobysnacks

1,195 Posts.

350

19/01/22

18:49

Post #: 58986215
Share

Originally posted by GMoney79: ↑

Thx @LT_Investor for providing this, and @nissassa for asking for it.

If you actually look at the Top 20 pre consolidation vs post consolidation the biggest change to me is Leonite Capital and UBS.

UBS have soaked 85m equivalent pre consolidation.

Leonite might have been the backers from last cap raise which explains their big jump. They held 13.8m pre consolidation, they now hold 142m on a like for like basis. If you check their website you can see some of their major investments - they’re pretty diversified.

http://leonitecap.com/portfolio

They’re also a US based investment firm who have seriously upped their stake in the last 3-4 months. Maybe this is what a US investment firm wanted to take a larger position was consolidation after all. If it is them and they were issued the full allotment, they’ve not flipped for pips or even sold into the last round of news - that being the Bonanza hits. By my calcs it would’ve been approx 109m shares issued in that raise, which aligns with their new total - and then some, so maybe some accumulation since then as well to get to 142m.

The main part for me is the likes of Peter Proska and other LONG TERM investors have not changed any of their holdings post consolidation. Feel free to do your own comparatives against the top 20 from the annual report, but just remember the lists in the annual report have Joe Bloggs & Jane Bloggs hold 10m shares combined. The list provided below splits them in 5m and 5m equivalent. So might explain why it’s slightly lower entry point.

But also good to see Chris now in this list, whilst they’re mostly performance based, he now has that skin in the game….

I’m viewing this as pretty positive, most appear to be holding strong - unless someone can show me the error of my ways?

Expand

NVA Price at posting: $1.10 Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 8 more messages in this thread...

First 97 Last

Add NVA (ASX) to my watchlist

(20min delay)
Last 16.5¢		Change 0.010(6.45%)		Mkt cap ! $44.86M

Open	High	Low	Value	Volume
16.0¢	16.5¢	15.8¢	$79.18K	492.9K

Buyers (Bids)

No.	Vol.	Price($)
1	34183	16.5¢

Sellers (Offers)

Price($)	Vol.	No.
17.0¢	18380	2

View Market Depth

No.	Vol.	Price($)
1	34183	0.165
2	87305	0.155
5	219938	0.150
4	138799	0.145
5	120527	0.140

Price($)	Vol.	No.
0.170	18380	2
0.175	23857	3
0.180	117642	1
0.190	33340	2
0.195	20000	1

Last trade - 16.10pm 07/10/2024 (20 minute delay)

NVA (ASX) Chart

Ann: Quarterly Activities Report and Appendix 5B - 30 Sept 21, page-97

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Activities Report and Appendix 5B - 30 Sept 21, page-97

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News